Discordance has been reported in human chorionic gonadotropin (hCG) concentrations measured by different immunoassay kits. We examined the results for 40 serum samples assayed with 10 different hCG immunoassay kits. Results varied considerably. Individual sample results varied by as much as 58-fold. Average results for different kits varied by as much as 1.4-fold for pregnancy (20 samples) and 2.2-fold for trophoblast disease (20 samples) serum. We investigated the causes of this discordance. hCG or hCG/3 are general names for mixtures of hCG, hCGa, or hCG/3 immunoreactive molecules in serum. These mixtures include regular hCG, nicked hCG (missing peptide linkages at /344-45 or p347-48), carbohydrate variants of hCG, hCG missing the /3-subunit C-terminal segment, free /3-subunit,13-corefragment, and free a-subunit. We prepared standards for each of these major variants and measured their reactivities in the 10 hCG immunoassay kits. Free 13-subunit reactivity varied from nonrecognition (anti-f3:anti-a type kits; Hybritech Tandem-R and others) to overrecognition (one kit had five-fold greater affinity for free /3than for hCG). Kits with antibodies to /3-subunit C-terminal segment (Organon NML and others) failed to recognize hCG missing this segment, a component of serum hCG in trophoblast disease. Kits with anti-hCG aptibodies (Serono MAIAclone and others) had minimal recognition of nicked hCG (12%), a component of all serum hCG samples, and consistently gave the lowest values with all serum samples. We conclude that differences in recognition of nicked hCG, free /3, and these other hCG variants cause discordance in hCG immunoassay results. Quantitative serum hCG measurements are used to monitor the progress of pregnancy; to assess the date of pregnancy; to screen for ectopic pregnancy, hydatidiform mole, and Down syndrome; and to follow the course of trophoblast disease, testicular cancer, and certain nontrophoblastic malignancies. For >20 years, competitive radioimmunoassays (RIAs) have been used to determine hCG concentrations in serum. In 1972 Vaitukaitis et al.
Quantitative serum hCG measurements are used to monitor the progress of pregnancy; to assess the date of pregnancy; to screen for ectopic pregnancy, hydatidiform mole, and Down syndrome; and to follow the course of trophoblast disease, testicular cancer, and certain nontrophoblastic malignancies. For >20 years, competitive radioimmunoassays (RIAs) have been used to determine hCG concentrations in serum. In 1972 Vaitukaitis et al. (1) developed the hCG/3 RIA, using antisera to hCGf3-subunit. This was the first assay to distinguish hCG from luteinizing hormone. In the mid-1970s the hCG/3 RIA became the standard test, and is still widely used today. The advent of monoclonal antibodies facilitated the development of more sophisticated and more specific immunoassays. Multiple-site sandwich assays were developed in which one or more immobilized antibodies "capture" the hCG and either radiolabeled (immunoradiometric assay, IRMA) or enzyme-labeled (immunoenzymometric assay, IEMA) antibodies detect the bound molecules (2) (3) (4) . In 1991 serum hCG could be measured by any one of five types of immunoassays, with >50 different commercial kits.
These types of assays were the hCG/3 RIAs and IRMAs or IEMA8 involving two different /3-subunit (anti-I3:anti-/3) antibodies, an a-and a /3-subunit (anti-/3:anti-a) antibody, a /3 C-terminus and a /3-subunit (anti-/3 C-terminus:anti-/3) antibody, or an hCG and a /3-subunit (antihCG:anti-/3) antibody.
Discordant results have been reported for the various hCG immunoassays, with different kits giving different values for the same serum sample. The problems and confusion created by discordant results are exemplified in an article by Painter (5) and in several other publications (6) (7) (8) (9) (10) (11) . In the past, discordance was attributed to differences in hCG standards [the 1st International Reference Preparation (IRP) for immunoassay (pure hCG), the 2nd International Standard (IS) for bioassay (crude urine extract), and othersJ and to interference by pituitary luteinizing hormone (6) (7) (8) (9) (10) (11) . Today (Table 1) . Here we consider the possibility that differences in recognition of each of these hCG variants by the five types of hCG immunoassays are the cause of discord in reported values.
Materials and Methods

Serum Samples
Serum was collected in the Obstetrics and Gynecology Infertility Clinic at Yale University from 10 women in early first-trimester pregnancy (five to eight weeks since their last menstrual periods). Samples were also collected at the Obstetrics and Gynecology Perinatology Clinic from 10 women with 14-to 20-week (secondtrimester) pregnancies and at the Gynecologic Oncology clinic from 10 women with hydatidiform mole (preevacnation) and from 10 women with persistent trophoblast disease (prechemotherapy). (27) or their distributors and used within seven days of receipt. The methods described in the instruction pamphlets were strictly followed except that the above-described amino acid analysis-calibrated standards were used. We used our published methods for the in-house 2119. 12/BP052 anti-aanti-a IRMA, the in-house B109/BP052 anti-hCG:anti-f3 IEMA, and the in-house CC11JHCO514 anti-a C-terminus:anti-IRMA (19, 20 serum samples was determined with the seven commercial hCG kits and the three in-house immunoassays. hCG standards CR119 and CR127 contain both nicked and intact hCG (Table 2 ) and may not be recognized equally by nick-sensitive and nick-insensitive assays. A new nick-free standard was needed. We chose P1 hCG, a preparation purified from pregnancy urine that is 100% intact (not nicked) and has no a-subunit or fl-subunit N-terminal heterogeneity (20) . P1 hCG standards were prepared and calibrated by amino acid analysis. We considered reasons for this discordance in hCG assay results. As indicated in Table 1 
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7820 (8678) 4900 (6737) 7185 (7384) 10920 (13736) 8360 (8770) 8395 (9226) 10080 (11443) 9405 (11245) 7100 ( to the p-subunit C-terminus (Organon NML and in-house CC11/BP052) had poor recognition of hCG missing the C-terminssl segment (-33% of CR119 hCG activity); one of the assays with an antibody to the fl-subunit C-terminus (Organon NML) had reduced recognition of asialo hCG (-55% of CR119 hCG activity); and the two anti-hCG: anti-fl assays (Serono MAJAclone and in-house B109/ BP052) had only minimal recognition of mcked hCG (-6% and -12% of CR119 hCG activity, respectively).
DIscussIon
We collected 40 individual serum samples, 20 from women with pregnancy and 20 from those with trophoblast disease, and tested them with 10 separate kite, two of each of the five major types of hCG immunoassay. Comparing results from different clinical centers is problematic, and the establishment and interpretation of clinical cutoff values and normal pregnancy hCG values has been hindered.
hCG, or hCGfl immunoreactivity, material is a mixtore of hCG a-and fl-subunit-related molecules (12-26). These include nicked hCG, carbohydrate-variants of hCG, and hCG missing the p-subunit C-terminal segment. As illustrated in Figure 3, tures (15,21,22,25) .
Carbohydrate variation can occur at any of the eight glycosylation sites on hCG a-and p-subunit (Figure 3) . Carbohydrate variants are major components of hCG in women with trophoblast disease (21, 25) . hCG molecules missing all or part of the p-subunit C-termin50l segment have also been detected in women with trophoblast disease (20) . Other curvesare forindividual hCG samples 100% nIcked (0) or missing the ft-subunit C-terminal segment (*) and for hCG ft-subunit standard batch CR129 (#{149}) and p-subunit core-fragment standard 88455 (G). Cross-reactivity values are given for deviant dose-response lines. Vekies are percent of CR119 dose determined at 50% radIoactivity bound (ED,). Approximate (-) and less than (<) values are given for dose-response lines that do not achieve 50% maxImum response. NSB. 4. Only one of the 10 kits (Organon NML, antip-subunit C-terminal segment:anti-fl assay) had significantly decreased activity with asialo hCG (-55% of CR119 hCG reactivity). Sensitivity to asialo hCG indicates sensitivity to differences in carbohydrate structure, e.g., structures missing sialic acid and structures with polyantennary core oligosaccharide components.
Such structures have been demonstrated on hCG molecules in trophoblast disease (15,21,22,25) .
A recent review by Hussa (6) We suspect that other anti-hC-G:anti-fl assays may act likewise. Second, different hCG kits vary in their recognition of hCG free /3-subunit.
Although kits of the anti-a:anti-fl type did not detect free /3-subunit, the Abbott hCG 15/15 anti-fl:anti-fl type assay detected p-subunit 4.9-fold more than it did hCG; this led to unduly high values with trophoblast disease samples.
Most anti-ftanti-fl assays detect free p-subunit, usually to the same extent as hCG. The Abbott assay may be an exception. Third, anti-fl C-terminus:anti-f3-type assays poorly detect hCG missing the p-subunit C-terminal segment, a variable component of trophoblast disease samples. One of 10 hydatidiform mole samples tested was very poorly recognized by this type of assay (values were 2.6% of the median value for the other eight assays). We infer that assays with exaggerated recognition of hCG free fl-subunit and those with an anti-fl C-terminus antibody should be avoided for testing trophoblast disease samples.
How can interkit discordance be avoided? Manufacturers should test kits with nicked hCG, hCG missing the C-terminal segment, and free /3-subunit standards.
Kits could then be labeled as specific for total hCG (all forms of hCG), intact hCG (nonnicked molecules), and (or) free /3-subunit. This would help establish hCG cutoff values and ease the interpretation of hCG concentrations reported by different laboratories or determined by different immunoassays.
